Everything you need to know about peptides and supplements — research-backed, clearly written, and regularly updated.
Everything that goes into tracking a protocol well — what to log, how to schedule it, rotating injection sites, and how to read your results.
What to record on every shot, how frequency and site rotation work, and how to time bloodwork so your numbers actually mean something.
Why rotation matters, where the SubQ and IM sites are, how to build a rotation that sticks, and how to actually keep track of it.
How titration works, how to stay on your phase and weekly schedule, rotating sites, and tracking side effects and progress.
What to log, how to time each one, building a schedule, and how to tell which supplements are actually doing anything.
How pump-based dosing works, counting pumps and doses, alternating nostrils, priming, and tracking what is left.
A synthetic fragment of body protection compound — what the research says, how to dose it, and where to get it.
The coenzyme behind cellular energy, DNA repair, and healthy aging — and how to restore levels that decline with age.
The mitochondrial-derived exercise mimetic — how it activates AMPK, improves metabolism, and why researchers call it the "exercise pill."
Marketed as a systemic tissue-repair peptide; commonly stacked with BPC-157 in community protocols for tendon, muscle, and ligament recovery.
The gold-standard GH peptide stack — a GHRH + GHRP combo that triggers natural pulsatile growth hormone release for better recovery, sleep, and body composition.
The copper-binding peptide famous for regenerating aged skin, thickening hair, and accelerating wound healing — used topically or injected.
The GLP-1 receptor agonist behind Ozempic and Wegovy — how it works, how to titrate safely, and what to expect from weekly dosing.
The dual GLP-1 / GIP agonist behind Mounjaro and Zepbound — delivering the largest weight-loss results seen in any approved medication to date.
The FDA-approved GHRH analog that specifically reduces visceral (belly) fat — originally developed for HIV patients and now widely used off-label for body composition.
The original GHRH peptide — well-tolerated, affordable, and still one of the best entry-level choices for improving sleep and recovery in midlife.
The melanocortin peptide that works on the brain rather than the bloodstream — FDA approved as Vyleesi for female sexual arousal, and widely used off-label for male libido.
The fat-loss fragment of growth hormone — provides the lipolytic effects of HGH without the blood sugar and growth-related side effects.
The Russian-developed longevity tetrapeptide — Khavinson-lineage data on telomerase activation in cultured fibroblasts and circadian/melatonin restoration in older adults. Single-lineage literature; independent replication is limited.
An oral small molecule that blocks NNMT — preserving cellular NAD+ and SAM levels, with early data for fat loss, muscle regeneration, and metabolic health.
The subcutaneous form of the NNMT inhibitor — the same route used in the original mouse studies. Why inject instead of swallow, SC dosing, reconstitution, and safety.
The immune-modulating peptide approved in 35+ countries — strengthens T-cell immunity without overstimulation, used for chronic infection, post-COVID recovery, and Lyme.
The cardiolipin-binding peptide that concentrates inside mitochondria and restores energy production — actively trialed for Barth syndrome, primary mitochondrial disease, and heart failure.
The Russian anxiolytic peptide used for stress, anxiety, and cognitive support — non-sedating, non-addictive, and active within 30 minutes of an intranasal dose.
The Russian nootropic peptide used for focus, cognition, and neuroprotection — sister peptide to Selank with a stronger stimulating profile.
The triple agonist (GLP-1 + GIP + glucagon) in Phase 3 trials — Phase 2 showed ~24% body-weight reduction at 48 weeks, and TRIUMPH-4 (knee-OA cohort) reported 28.7% at 68 weeks.
The melanocortin peptide used for sunless tanning and libido enhancement — powerful results, but a side-effect profile that demands careful titration.
The amylin analog that pairs with semaglutide for even greater appetite suppression and fat loss — the foundation of the "CagriSema" stack.
The oral triple monoamine reuptake inhibitor originally developed for Parkinson’s — now used off-label for aggressive fat loss, with Phase 2 data showing up to 12.8% body weight reduction.
The cleanest GHRP ever made — triggers a natural GH pulse without the cortisol, prolactin, or hunger spikes that plague older growth-hormone peptides.
The lipotropic "fat-melting" injection used in medical weight-loss clinics for decades — a blend of methionine, inositol, choline, and B12 that supports fat metabolism.
The anti-inflammatory tripeptide derived from alpha-MSH — widely used for IBD, gut healing, eczema, psoriasis, and any condition driven by chronic inflammation.
The master antioxidant peptide your liver uses to detoxify everything — now used as an injectable to support liver function, skin tone, and oxidative stress.
The community-popular "Wolverine" peptide blend — BPC-157 (conventionally treated as local) plus TB-500 (conventionally treated as systemic). Used in community injury-recovery and post-op protocols; no Phase 2/3 human data.
A community-marketed three-peptide blend — BPC-157 + TB-500 + GHK-Cu. Sold as a single vial; the combination has no published human evidence and is component-extrapolated throughout.
GLOW with KPV added — a community four-peptide blend marketed for inflammatory skin conditions and advanced recovery. The combination has no published human evidence and is component-extrapolated.
The premium GHRH + GHRP stack — tesamorelin’s visceral-fat-targeting firepower plus ipamorelin’s clean GH pulse. The most potent pulsatile GH protocol short of actual HGH.
The Korean fat-dissolving injection that went viral for targeted spot-reduction — double chin, jawline, bra fat, love handles, and other stubborn pockets that diet and exercise won’t touch.
The synthetic ERR agonist popularly dubbed “exercise in a pill” based on preclinical mouse studies. Important caveat: the Burris-lab successor SLU-PP-915 paper (PMID 41421047) explicitly states SLU-PP-332 itself lacks oral bioavailability — community oral dosing is not pharmacologically supported by the originating literature.
The copper peptide more selective for hair follicle activation than GHK-Cu — used topically on the scalp for thicker, faster-growing hair and in combination with minoxidil and microneedling.
A Russian bioregulator tripeptide (Ala-Glu-Asp) marketed for cartilage and joint support — part of the Khavinson family, used in 10–20 day cycles. Khavinson-lineage data; no peer-reviewed Western RCT.
A Khavinson bioregulator (synthetic KEDG, Lys-Glu-Asp-Gly) — the "testicular" community-marketing positioning is not supported by published KEDG literature, which actually describes anterior-pituitary-derived effects on TSH/T3/T4, thymus, and immunity.
The 28-amino-acid neuropeptide used in Ritchie Shoemaker’s CIRS protocols — powerful anti-inflammatory, vasodilator, and autonomic regulator for chronic inflammatory illness.
A Khavinson bioregulator (synthetic KEDP) marketed for prostate tissue — short cycles for age-related prostate function, urinary support, and BPH symptoms. Most prostate-RCT clinical evidence is for the parent extract Prostatilen / Vitaprost, not synthetic KEDP.
The prescription foundation of male HRT — how TRT works, what clinical dosing looks like, and how to find a qualified provider who actually runs the right labs.
Recombinant human growth hormone — clinically approved for specific deficiencies, frequently misused for anti-aging. Here’s how it actually works and what responsible access looks like.
The prescription gonadotropin used alongside TRT to preserve testicular size and fertility — and to restart natural production after a cycle.
An old opioid antagonist repurposed at tiny doses as an immunomodulator — widely used off-label for autoimmune conditions, chronic pain, and long-COVID recovery.
The cornerstone of hypothyroidism treatment — T4, T3, and NDT: how each works, clinical dosing, monitoring, and how to find a provider who actually tests Free T3.
The primary estrogen used in menopausal hormone therapy and gender-affirming care — every delivery form, what the modern evidence actually shows, and how to work with a knowledgeable provider.
The often-underrated half of menopause HRT — protects the uterus from unopposed estrogen, supports sleep, and is available as bioidentical micronized progesterone.
The adrenal prohormone that declines with age — OTC in the US, prescription elsewhere, and the hormone replacement most people try first.
The potent older-generation GHRP — bigger GH pulse than ipamorelin, but with cortisol and prolactin elevations that have pushed most users to cleaner alternatives.
The older-generation GHRPs — GHRP-2 is the pharma-developed version (pralmorelin), GHRP-6 is the hunger-inducing outlier. Both have largely been replaced by ipamorelin in modern protocols.
The two IGF-1 analogs popular in bodybuilding — LR3 for sustained systemic IGF-1 elevation, DES for localized pre-workout hypertrophy.
The IGF-1 splice variant produced by mechanically loaded muscle — MGF for post-workout local action, PEG-MGF for twice-weekly systemic dosing.
The nine-amino-acid peptide originally isolated from sleeping rabbits — studied for decades as a deep-sleep enhancer, though Western research has never fully embraced the claims.
The "love hormone" — endogenous bonding peptide also prescribed as Pitocin for labor induction, and used off-label for social connection, orgasm intensity, and mood.
The HPG-axis master regulator — acts upstream of LH and FSH to restore natural reproductive-hormone function, with emerging clinical data in fertility and libido research.
The human cathelicidin antimicrobial peptide — endogenous first-line defense that’s become an off-label tool for chronic infections, biofilm disruption, and immune protocols.
The oldest drug in the modern pharmacopoeia — now a hot topic for mitochondrial support, cognition, and photobiomodulation synergy. Just watch the SSRI interaction.
The Russian-developed thymic polypeptide extract — related to but distinct from Thymosin Alpha-1, with decades of Eastern European clinical use in immune restoration and longevity protocols.
A Khavinson tripeptide (Glu-Asp-Arg) marketed for brain tissue — short cycles for cognitive maintenance and neuroprotection. Khavinson-lineage data, limited independent replication.
The porcine brain hydrolysate prescribed across Europe and Asia for stroke, TBI, and dementia — a cocktail of neuropeptides and amino acids that doesn’t quite fit the single-peptide mold.
The FDA-approved cousin of MT-2 — more selective for MC1R, meaning cleaner tanning effect with fewer libido / nausea side effects. Approved as Scenesse for EPP; used off-label for sun sensitivity and tanning.
The AMPK activator that made "exercise in a bottle" headlines in the 2000s — real mechanism, real animal data, but dose-cost and limited human trials keep it experimental.
The 11-amino-acid fragment of erythropoietin stripped of the red-blood-cell side effect — a tissue-protective peptide in active clinical development for diabetic neuropathy and sarcoidosis.
The experimental senolytic peptide — disrupts FOXO4-p53 binding in senescent cells to trigger their apoptosis. Real mechanism, mouse data, practically no human clinical data.
The peptide that cuts the blood supply to white fat tissue — dramatic preclinical weight loss but kidney toxicity signals that stalled its clinical development.
The amino-acid derivative that ferries fatty acids into mitochondria — oral forms are OTC, injectable carnitine has its own loyal following for fat loss and exercise recovery.
The glycosaminoglycan that lubricates joints and plumps skin — FDA approved as an injectable medical device for knee OA and as a cosmetic dermal filler. Both are provider-administered.
The pharmaceutical-grade peptide diluent. Hospira/Pfizer Bacteriostatic Water (NDA 018802) is the FDA-approved standard — sterile water + 0.9% benzyl alcohol that lets you re-puncture a multi-dose vial for ~28 days. Here’s when to use it, when not to, and why neonates have a black-box history with this preservative.
The vitamin that’s a real treatment for real deficiency — and a heavily marketed “energy boost” in non-deficient adults where the controlled-trial evidence is essentially absent. Honest framing on both sides, plus the form-by-form FDA status (cyanocobalamin yes, methylcobalamin no).
The FDA-approved fertility gonadotropin (Menopur, Ferring) used in IVF stimulation, male hypogonadotropic hypogonadism, and off-label after TRT cessation. Combination of FSH and LH-like activity — with a real pharmacology nuance: per the FDA label, that LH-like activity is largely hCG, not LH itself.
A modified GHRH(1-29) tetrasubstituted analog — sold under one name in two pharmacologically very different forms. The no-DAC version pulses (~30 min). The with-DAC version saturates the GHRH receptor for 6–8 days. Neither has FDA approval; both are WADA-prohibited; the 2006 Phase 2 program ended after a participant death.
A research peptide built by combining Semax with the adamantyl cap from P21. There’s no published research on the Adamax molecule itself — what we know comes from the parents.
Lys-Glu-Asp-Trp (KEDW), a Khavinson short peptide proposed as a β-cell and glucose-tolerance bioregulator. Russian preclinical work plus one small elderly-T2DM cohort study, no Western clinical replication. Investigational.
The original synthetic ghrelin-receptor agonist (Bowers, Tulane, 1984) — the molecule that <em>predicted</em> the existence of ghrelin. Its real distinguishing feature among the older GHRPs is a strong central appetite signal, not exceptional cortisol or prolactin elevation.
des(1-3)IGF-I — native IGF-I missing the N-terminal Gly-Pro-Glu tripeptide. IGFBP-resistant and short-acting, the kinetic opposite of LR3. Naturally occurring (bovine colostrum, human fetal brain), but not FDA-approved for any indication and prohibited under WADA S2.3.
A research-tier construct: the 24-aa MGF E-peptide of IGF-1Ec conjugated to polyethylene glycol. Zero PubMed papers on PEG-MGF as a discrete entity. Inherits the contested Goldspink / Fornaro reproducibility debate and adds an unmeasured PEGylation layer on top.
A 24-amino-acid mitochondrial-derived peptide encoded by the 16S rRNA mitochondrial gene — first described in 2001 by the Hashimoto / Nishimoto group at Keio from a cDNA library of an Alzheimer brain region that was unusually <em>spared</em> from disease.
A non-steroidal selective androgen receptor modulator (SARM) developed by Radius Health, now with Ellipses Pharma as <em>vosilasarm</em>. The published human harm evidence — four DILI case reports plus a myocarditis case and a gynecomastia / HPTA case — outweighs the published human benefit evidence (one Phase 1 partial response in 22 patients).
The world's first GLP-1 / glucagon dual receptor agonist approved anywhere — NMPA-approved in China on 27 June 2025 for obesity and again in September 2025 for type 2 diabetes. Not FDA-approved, not EMA-approved. Investigational drug for US/EU users.
An endogenous secreted glycoprotein that binds and neutralizes myostatin and activins. Real clinical evidence comes from gene therapy (Sarepta / Nationwide Children's AAV1-FS344) — not from injected protein. The "FST-344" sold gray-market is a different molecule with zero published human PK or safety data, and a 2019 WADA-lab forensic study found only 9 of 17 vendor products actually contained follistatin.
A Burris-lab Rev-erbα agonist tool compound from Scripps Florida (Solt 2012). Coherent mouse data, but two facts dominate: oral F% ~2.2% kills any oral protocol, and Dierickx 2019 showed substantial Rev-erb-<em>independent</em> activity in receptor-knockout cells.
Boehringer Ingelheim × Zealand Pharma GLP-1 / glucagon dual agonist in Phase 3 development. Strong Phase 2 NEJM MASH signal (62% MASH improvement at 4.8 mg) and FDA Breakthrough Therapy Designation for non-cirrhotic MASH (Sept 2024). Not yet approved anywhere.
A PPARδ agonist whose pharmaceutical sponsor walked away from Phase 2 development around 2007–2008 because of multi-organ rodent tumors at clinically relevant exposures. WADA issued an unprecedented compound-specific public alert on 21 March 2013.
An AngIV-derived peptidomimetic with two compounding credibility problems: foundational mechanism paper retracted April 2025, and the dihexa-derived prodrug fosgonimeton failed Phase 2/3 LIFT-AD in September 2024. Mechanism is direct activation of c-Met — one of the most-studied oncogenic receptor tyrosine kinases in solid tumors.
An Acceleron Pharma ActRIIB-Fc fusion protein (~110–115 kDa, not a peptide). Its only Phase 2 trial — in ambulatory boys with Duchenne muscular dystrophy — was halted in February 2011 for a vascular-leak phenotype. Program terminated 2013. StackTrax does not recommend ACE-031 use.
A small-molecule investigational drug originally identified by phenotypic screening for hippocampal neural-stem-cell proliferation. Two registration-grade MDD trials missed primary endpoints (Neuralstem Phase 2 2020; Alto Neuroscience Phase 2b 2024). Direct molecular target never publicly disclosed.
A 9-amino-acid zinc-dependent thymic nonapeptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), originally isolated as Facteur Thymique Sérique (FTS) from porcine serum by the Bach group at Hôpital Necker (Paris) in 1977. Never approved as a drug anywhere. Substantial preclinical literature; limited dated human data.
A tripeptide (Pro-Leu-Gly-NH2) that is also the C-terminal tail of oxytocin. Originally identified as an amphibian MSH-release inhibitor; modern interest is as a positive allosteric modulator of D2 dopamine receptors. Small 1970s/80s human trials in Parkinson's and depression; never approved as a drug.
The N-acetylated derivative of Selank (parent: TKPRPGP, the Russian Academy of Sciences anxiolytic). Zero PubMed-indexed primary literature on the N-acetylated form itself. Every "stronger / longer-acting" claim is medicinal-chemistry intuition plus parent-Selank pharmacology imported wholesale.
N-acetylated derivatives of Semax (parent: MEHFPGP, the Russian Academy ACTH(4–7) analog). Zero published pharmacology on the N-acetyl forms themselves. The one direct chemistry paper (Magrì 2016) shows N-acetylation changes Cu(II)/Zn(II) coordination — so the modified molecule isn't pharmacodynamically identical to parent Semax, but direction never measured.
A 7-amino-acid peptide (GVSWGLR) derived from the C-terminal tail of spadin, a fragment of the sortilin (NTSR3) propeptide. Mechanism: TREK-1 (KCNK2) two-pore-domain potassium channel inhibition — not BDNF signaling, despite widespread vendor framing.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information